The company intends to use the funds for the further development and clinical roll-out in Europe and the USA of the second generation AMYCARD system, a CE Mark-approved diagnostic device.
Led by Dr. Werner Rainer, board member and CEO ad interim, Dr. Joaquin Azpilicueta, MD, MBA as COO, and Drago A. Cerchiari, Ph.D., chairman of the board, EP-Solutions is primarily focused on the The EP-Solutions system allowing for simultaneous electrophysiology mapping on both epicardial and endocardial surfaces of the heart. The company’s real-time cardiac mapping technology is based over 6 years of clinical research with more than 750 patients.
Founded in 2009 under the name of Amycard, EP-Solutions was then incorporated in Switzerland as EP-Solutions after the acquisition and transfer of assets of Amycard.
FinSMEs
20/12/2016